The purpose of this study is to explore and develop a novel biocompatibility drug delivery carrier for controllingontrolled drug release. The a-eleostearic acid grafted hydroxyapatite （a-ESA-g-HA） composite was synt...The purpose of this study is to explore and develop a novel biocompatibility drug delivery carrier for controllingontrolled drug release. The a-eleostearic acid grafted hydroxyapatite （a-ESA-g-HA） composite was synthesized by using silane coupling agent and characterized by Fourier Transformation Infrared Spectroscopy （FT-IR）, Thermal Gravimetric Analysis （TGA） and Scanning Electron Microscope （SEM）, respectively. The in vitro drug loading and controlled release behaviors of a-ESA-g-HA composite were investigated using ciprofloxacin as the model drug. The amount of ciprofloxacin loading and released was cal- culated by absorbance value which was determined by UV-Vis spectrophotometry at wavelength of 277 nm. The biocompatibility of a-ESA-g-HA composite was assessed by 3-（4,5）-dimethylthiahiazo（-z-yl）-3,5-di-phenytetrazoliumromide（MTT） assay, nuclear morphology and platelet adhesion. The results showed that the a-ESA-g-HA had nontoxic and good biocompatibility. According to the results mentioned above, the a-ESA-g-HA is an effective drug delivery carrier, which could increase drug loading capacity and control drug release, so further studies are necessary to evaluate clinical application and human health care.展开更多
文摘The purpose of this study is to explore and develop a novel biocompatibility drug delivery carrier for controllingontrolled drug release. The a-eleostearic acid grafted hydroxyapatite （a-ESA-g-HA） composite was synthesized by using silane coupling agent and characterized by Fourier Transformation Infrared Spectroscopy （FT-IR）, Thermal Gravimetric Analysis （TGA） and Scanning Electron Microscope （SEM）, respectively. The in vitro drug loading and controlled release behaviors of a-ESA-g-HA composite were investigated using ciprofloxacin as the model drug. The amount of ciprofloxacin loading and released was cal- culated by absorbance value which was determined by UV-Vis spectrophotometry at wavelength of 277 nm. The biocompatibility of a-ESA-g-HA composite was assessed by 3-（4,5）-dimethylthiahiazo（-z-yl）-3,5-di-phenytetrazoliumromide（MTT） assay, nuclear morphology and platelet adhesion. The results showed that the a-ESA-g-HA had nontoxic and good biocompatibility. According to the results mentioned above, the a-ESA-g-HA is an effective drug delivery carrier, which could increase drug loading capacity and control drug release, so further studies are necessary to evaluate clinical application and human health care.
